Actively Recruiting

Age: 18Years +
All Genders
NCT05744466

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Led by Bristol-Myers Squibb · Updated on 2024-07-23

1500

Participants Needed

1

Research Sites

271 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.

CONDITIONS

Official Title

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with plaque psoriasis by a dermatologist
  • Newly starting treatment with either deucravacitinib or apremilast
  • Actively enrolled in the CorEvitas Psoriasis Registry with consent for research use of registry data
Not Eligible

You will not qualify if you...

  • Currently participating or planning to participate in an interventional clinical trial (excluding observational studies)
  • Restarting treatment with deucravacitinib or apremilast previously received at any time

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Local Institution

Waltham, Massachusetts, United States, 02451

Actively Recruiting

Loading map...

Research Team

B

BMS Study Connect Contact Center www.BMSStudyConnect.com

CONTACT

F

First line of the email MUST contain the NCT# and Site #.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here